Literature DB >> 26139425

Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.

Theodor Bokic1, Martin Storr, Rudolf Schicho.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is currently one of the most common disorders of the digestive system in the Western society. Almost 2 out of 10 people suffer from IBS with women being more affected than men. IBS is associated with abdominal pain, bloating and altered stool consistency and imposes a heavy burden for the affected patients.
SUMMARY: The pathophysiology of IBS remains elusive although potential causes have been suggested, such as a deranged brain-gut signaling, hypersensitivity of visceral sensory afferent fibers, bacterial gastroenteritis, small intestinal bacterial overgrowth (SIBO), genetic alterations and food sensitivity. Targets for the pharmacotherapy of IBS include the serotonergic and opioidergic system, and the microbial population of the gut. Alternative therapies like traditional Chinese medicine have shown some success in the combat against IBS. Key Messages: Many therapeutics for the treatment of IBS have emerged in the past; however, only a few have met up with the expectations in larger clinical trials. Additionally, the multifactorial etiology of IBS and its variety of cardinal symptoms requires an individual set of therapeutics. This review provides a short overview of potential causes and current pharmacological therapeutics and of additional and alternative therapies for IBS.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26139425      PMCID: PMC4541721          DOI: 10.1159/000435816

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  125 in total

1.  Irritable bowel syndrome: a global view.

Authors:  Ronnie Fass
Journal:  J Gastroenterol Hepatol       Date:  2003-09       Impact factor: 4.029

Review 2.  Peripheral mechanisms in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

Review 3.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

4.  Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli.

Authors:  Sigrid Elsenbruch; Christina Rosenberger; Ulrike Bingel; Michael Forsting; Manfred Schedlowski; Elke R Gizewski
Journal:  Gastroenterology       Date:  2010-06-22       Impact factor: 22.682

5.  Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome.

Authors:  T K Klooker; S D Kuiken; A Lei; G E Boeckxstaens
Journal:  Aliment Pharmacol Ther       Date:  2007-08-15       Impact factor: 8.171

6.  Use of oral sodium cromoglycate in persistent diarrhoea.

Authors:  T D Bolin
Journal:  Gut       Date:  1980-10       Impact factor: 23.059

Review 7.  Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  A C Ford; N J Talley; P S Schoenfeld; E M M Quigley; P Moayyedi
Journal:  Gut       Date:  2008-11-10       Impact factor: 23.059

8.  Relationship between irritable bowel syndrome, worry and stress in adolescent girls.

Authors:  Sang-Wook Song; Seo-Jin Park; Se-Hong Kim; Sung-Goo Kang
Journal:  J Korean Med Sci       Date:  2012-10-30       Impact factor: 2.153

9.  Prevalence of functional bowel disorders and faecal incontinence: an Australian primary care survey.

Authors:  K-S Ng; N Nassar; K Hamd; A Nagarajah; M A Gladman
Journal:  Colorectal Dis       Date:  2015-02       Impact factor: 3.788

10.  Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth.

Authors:  Victor Chedid; Sameer Dhalla; John O Clarke; Bani Chander Roland; Kerry B Dunbar; Joyce Koh; Edmundo Justino; Eric Tomakin; Gerard E Mullin
Journal:  Glob Adv Health Med       Date:  2014-05
View more
  3 in total

Review 1.  Low fermentable oligosaccharides, disaccharides, monosaccharides, and polypols diet and irritable bowel syndrome in Asia.

Authors:  Yihe Zhang; Zheng Feei Ma; Hongxia Zhang; Binyu Pan; Yeshan Li; Hazreen A Majid; Yeong Yeh Lee
Journal:  JGH Open       Date:  2018-12-28

2.  The Protective Effect of Melissa officinalis L. in Visceral Hypersensitivity in Rat Using 2 Models of Acid-induced Colitis and Stress-induced Irritable Bowel Syndrome: A Possible Role of Nitric Oxide Pathway.

Authors:  Fatemeh Dolatabadi; Amir H Abdolghaffari; Mohammad H Farzaei; Maryam Baeeri; Fatemeh S Ziarani; Majid Eslami; Mohammad Abdollahi; Roja Rahimi
Journal:  J Neurogastroenterol Motil       Date:  2018-07-30       Impact factor: 4.924

Review 3.  Treating irritable bowel syndrome through an interdisciplinary approach.

Authors:  Dominika Dorota Nelkowska
Journal:  Ann Gastroenterol       Date:  2019-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.